Skip to content

Testing the antioxidant efficacy, skin anti-aging effects and safety of the Ferona W dietary supplement in women: a randomized controlled clinical trial

Testing the antioxidant efficacy, skin anti-aging effects and safety of the Ferona W dietary supplement in women: a randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20241103003
Enrollment
30
Registered
2024-11-03
Start date
2024-12-16
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy condition Women Healthy volunteers

Interventions

The Ferona W product is a dietary supplement according to Thai Food and Drug Administration.,Placebo contains no active ingredient.
Ferona W dietary supplement,Placebo

Sponsors

CMH Life Science Co., Ltd.
Lead Sponsor
Science &amp
Collaborator
Technology Park (STeP), Chiang Mai University
Collaborator

Eligibility

Sex/Gender
Female
Age
35 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Age between 35-55 years; 2. Has body mass index within the range of 18.5-24.9 kg/m2; 3. Has general good health based on medical history, physical examination, and basic laboratory tests; and 4. Able to provide written informed consent

Exclusion criteria

Exclusion criteria: 1. Has a presence of any severe co-morbidity(ies), uncontrolled medical condition(s), or medical illness(es); 2. Has a history of hypersensitivity to any ingredients in the investigational product; 3. Has a history of alcoholism, heavy smoking, or substance use within the past 3 months; 4. Uses a drug(s), herb(s), vitamin(s), mineral(s), or dietary supplement(s) and/or other ingredients regularly that may affect antioxidant capacity and the facial skin within 30 days; 5. Uses contraceptive pill or hormonal treatments within the past 3 months; 6. Uses antibiotic drugs or immunosuppressant drugs or steroids; 7. Has an aesthetic intervention (i.e., injections of Botulinum toxin, injection of dermal fillers, mesotherapy injection, laser therapy, and other treatments); 8. Has any physical attributes or skin conditions that might interfere with the clear visual (i.e., skin lesion, cuts, sunburn, birthmarks, tattoos, and extensive scarring); 9. Participates in another clinical trial concurrently or within 30 days; and 10. Has a plan to have a baby, or known or suspected pregnancy, or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Antioxidant capacity Baseline, Week 4, and Week 12 ELISA

Secondary

MeasureTime frame
Skin parameters Baseline and Week 12 Visiometer, Corneometer, Visioface, Visiopor, Colorimeter, TEWA meter, Cutometer, and/or Mexameter,Safety parameters Week 4 and Week 12 Physical examination and laboratory assessments,Satisfaction Week 4 and Week 12 Questionnaire

Countries

Thailand

Contacts

Public ContactNut Koonrungsesomboon

Chiang Mai University

nkoonrung@gmail.com053935353

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026